So, whatever happened to ESPR?
I often wonder the same thing.
It would take more digging than I could muster to find out the status of Esperion's programs and employees after they were absorbed into PFE's gargantuan folds. I suspect that some of the ESPR work is being reconsidered for its development potential with doubt increasing about the prospects for torcetrapib.
We know that at least one of the principals, Johannsen, is now Sr. VP at Resverlogix, a Canadian company that believes it is making further advances in developing small molecules that modulate HDL synthesis (as opposed to the direct HDL analogues that were in ESPR's pipeline).
Market Data 
Markets 
AI
